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Abstract
Background: Helicobacter pylori eradication rates in Portugal are declining, due to increased resistance of this
bacterium to antimicrobial agents, especially Clarithromycin. Quadruple Levofloxacin-containing regimens could
be an option for first-line treatment, but its efficacy should be evaluated as fluoroquinolone resistance is rapidly
increasing.
Our aim was to compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadruple therapies as
first-line treatment options and determine factors associated with treatment failure.
Methods: A total of 200 Helicobacter pylori infected patients were retrospectively included (female 57.5%;
average age: 53.2 ± 15.7) and received either 10-day sequential therapy (Proton-Pump Inhibitor + Amoxicillin
1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg
bid/tid in the following 5 days; group A) or a 10-day modified sequential therapy with Levofloxacin 500 mg
id instead of Clarithromycin (group B). Eradication was confirmed with urea breath test. Variables that could
influence success rate were analyzed.
Results: There were no differences between groups in terms of gender, age, smoking habits and indications
for treatment. The eradication rate obtained with Clarithromycin-based sequential treatment was significantly
higher than with Levofloxacin-based therapy (90%, CI95%: 84–96% vs. 79%, CI95%: 71–87%, p = 0.001). Using
full-dose proton-pump inhibitor and high-dose Metronidazole in group A, and full-dose proton-pump inhibitor
and prescription from a Gastroenterologist in group B were associated with eradication success.
Conclusions: Ten-day Levofloxacin-based sequential treatment achieved inadequate efficacy rate (<80%) and
should not be adopted as first-line therapy. Standard sequential therapy showed significantly better results in
this naïve population. Using full-dose proton-pump inhibitor and higher doses of Metronidazole is essential to
achieve such results.
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Background
Helicobacter pylori (H. pylori) is a Gram negative, micro-
aerophilic bacterium that is presumed to infect from
one-third to over half of the world’s population [1]. It is
known to be a major responsible for a significant
number of gastric pathologies, but its role in extra-
gastric diseases is also becoming well documented. H.
pylori leads to an inflammatory state, induces molecular
mimicry and alters the absorbance of several nutrients
[2]. These discoveries are increasing physicians’ aware-
ness to the need to eradicate this bacterium.
Initially, the adopted treatment to eradicate H. pylori,
the so-called ‘legacy’ triple therapy with a proton-pump
inhibitor (PPI), Clarithromycin and Amoxicillin was
quite effective. However, in the last 10 years, its’ efficacy
has decreased to unacceptable levels in many countries,
especially due to increasing levels of bacterial resistance
[3]. Excessive and misjudged use of antibiotics contrib-
uted to this decreased susceptibility, leading to 50%
resistance rates to Clarithromycin in the central region
of Portugal (primary 21.4%; secondary 88.3%) [4].
Accordingly, current guidelines recommend bismuth-
containing quadruple therapies or, alternatively, sequen-
tial or non-bismuth quadruple therapy, if Clarithromycin
resistance is above the 15–20% threshold [5]. Unfor-
tunately, H. pylori antibiotic resistance has reached
alarming levels not only for macrolides but also to
other drugs. Metronidazole resistance has been stable
in Europe, reaching 34.9% of H. pylori isolates. Fortu-
nately, its impact on the success of eradication regi-
mens is limited, as it can be overcome by prolonging
duration of treatment or increasing the dosage of
Metronidazole [6]. Despite obtaining adequate eradi-
cation rates, standard sequential treatment should not
be prescribed if the combined Clarithromycin and
Metronidazole resistance is over 5% (which is the case
in several European countries) [6]. To overcome these
problems, some physicians prefer prescribing an adapted
sequential treatment with Levofloxacin instead of
Clarithromycin, as quinolones have been suggested as an
alternative in both first- and second-line regimens [7].
Patients with reported history of penicillin allergy were
also often prescribed with such regimens. Regrettably,
resistance rates to quinolones also reached worrisome
figures in Portugal and in Europe, reflecting its
ubiquitous use for minor respiratory and urinary
infections. According to Almeida et al [4], overall re-
sistance to Levofloxacin in the center of Portugal is
currently 33.9% (primary: 26.2%; secondary: 44.2%).
Facing such adverse ecological scenario, our aim was
to compare the efficacy of Clarithromycin and
Levofloxacin-based sequential quadruple therapies as
first-line treatment options and determine factors as-
sociated with treatment failure.
Methods
Study design
This retrospective study was conducted at the Coimbra
University Hospital from January 2014 to December 2015.
Adult patients with infection by H. pylori defined by
histology or 13C-urea breath test (UBT) and treated with
either standard sequential treatment (SST; group A) or
Levofloxacin-based sequential treatment (LST; group B)
were considered for inclusion. The treatment regimen was
chosen according to their physicians’ preference. Other
inclusion criteria were: (1) age over 18 years-old, (2)
absence of known allergies for antibiotics used in either
regimen, (3) signed informed consent. A total of 358 pa-
tients treated with one of these regimens were interviewed
after treatment completion (group A – 250 patients;
group B – 108 patients). Collected data included age,
gender, smoking and alcohol consumption, indication for
treatment, side effects and adherence. In order to obtain
two groups with similar dimension, and therefore avoid
statistical bias, we opted to include 100 patients in each
group. The selection of patients was performed randomly,
using SPSS software (as detailed below). Eradication
therapy was prescribed by Gastroenterologists or other
physicians working in our hospital.
The exclusion criteria were: (1) patients with previous
H. pylori eradication attempts; (2) patients treated with
proton-pump inhibitor (PPI), H2 receptor antagonist or
antibiotics in the 4 to 6 weeks previous to UBT; (3)
patients that interrupted the treatment before comple-
tion for any reason; (4) non-adherence to treatment. The
stricter definition of non-adherence was used, and
patients that failed at least one dose of medication were
excluded.
All patients were submitted to UBT at least 2 months
after completing treatment. The primary outcome of the
study was the eradication rate of H. pylori infection with
SST and LST. Finding factors associated with treatment
failure was the secondary outcome.
Therapeutic regimens
Patients in group A were treated with standard sequen-
tial therapy (SST) for 10 days: PPI twice daily + Amoxi-
cillin 1 g twice daily for 5 days; followed by PPI twice
daily + Clarithromycin 500 mg twice daily +Metronida-
zole 500 mg twice / thrice daily or Tinidazole 500 mg
twice daily for five more days. Group B patients were
treated with Levofloxacin-containing sequential therapy
(LST) for 10 days: PPI twice daily + Amoxicillin 1 g twice
daily for 5 days followed by PPI twice daily + Levo-
floxacin 250 mg twice daily +Metronidazole 500 mg
twice / thrice or Tinidazole 500 mg twice daily for five
more days. The choice between different PPI’s, Metro-
nidazole or Tinidazole and its dosage was made by the
prescribing physician.
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Statistical analysis
Statistical analysis of the results was performed using chi-
square test, Student’s t-test and Fisher’s exact test as well
as binomial logistic regression for multivariate analysis.
For all analysis, P values <0.05 were considered significant.
The 95% confidence intervals (CIs) were calculated by
normal approximation. The analysis was performed using
SPSS for Windows (version 21; SPSS Inc.).
Results
Study population
These groups were compared regarding demographic and
clinical characteristics, as described in Table 1. There was
no significant age or gender difference between both
groups. The same can be said for smoking habits and alco-
hol consumption (defined as more than 10 cigars/day and
>20 g alcohol each day). The main indication for prescrib-
ing eradication therapy was non-ulcer dyspepsia in both
groups. First-generation and full-dose PPI were preferred
in both the SST and the LST regimens. There were
significant differences in the choice of the nitroimidazole
antibiotics: Tinidazole was prescribed more often in both
groups, but especially in group B (p = 0.001). The most
used dosage for Metronidazole was 500 mg three times
a day in both groups. The majority of the prescribing
physicians were Gastroenterologists, especially in group
B (p = 0.002).
Efficacy of eradication therapy
The overall eradication rate was 84.5% (169/200). The
eradication rates were 90% (90/100) for group A and 79%
(79/100) for group B. Standard sequential therapy was
more effective than Levofloxacin-based modified sequen-
tial therapy (p = 0.03; OR = 2.39; IC95% = 1.06–5.38).
Factors associated with eradication failure
In group A, the use of Metronidazole instead of Tinidazole
(p = 0.006; OR = 10.15; IC95%:1.34–77.15), a lower dose of
Metronidazole (p = 0.001; OR = 8.25; IC95% = 1.95–34.81)
and not using an adequate dosage of PPI (p = 0.001;
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OR = 10.11; IC95% = 3.60–28.41) were risk factors for
eradication failure – as described in Table 2. Multivariate
analysis confirmed that half-dose PPI (p = 0.001; OR =
16.25; IC95% = 2.91–89.21) and a lower dose of Metro-
nidazole (p = 0.007; OR = 13.58; IC95% = 2.07–89.04) were
associated with unsuccessful eradication (Table 2). In
group B, half-dose PPI and prescription from non-
Gastroenterologists were the two factors associated with
unsuccessful eradication (p = 0.001; OR = 3.67; IC95% =
1.86–7.22 and p = 0.017; OR = 3.68; IC95% = 1.81–7.50,
respectively). Only the use of half-dose PPI was asso-
ciated with unsuccessful eradication in multivariate
analysis (p = 0.011; OR = 5.69; IC95% = 1.48–21.90).
Discussion
In southern European countries, such as Portugal, with
alarming resistance rates to most commonly used antibi-
otics, recommending an effective first-line treatment for
H. pylori eradication is becoming increasingly difficult.
Taking into account resistance rates to Clarithromycin
of over 30%, an alternative quadruple regimen with
Levofloxacin could be an effective option. However, with
a resistance rate to Levofloxacin over 25%, its utility may
be compromised. But if the resistance rates to Clarithro-
mycin and Levofloxacin are similar, why did the two
therapies showed such different results? Probably this is
due to the interaction between Amoxicillin and Clari-
thromycin. Amoxicillin acts on the bacterial wall,
destroying a transmembrane efflux system that allows
elimination of Clarithromycin in resistant bacterium.
Therefore there is a higher intracellular concentration of
Clarithromycin which can overcome other resistance
mechanisms [8]. The first 5 days of Amoxicillin act as
an inductor for the following 5 days of Clarithromycin.
This is probably the reason behind the ability of the
sequential regimen to eradicate a significant percentage
of Clarithromycin-resistant strains (as high as 82%
according to Zullo et al [9]). Interestingly, our results
are quite different from those obtained in a randomized
trial conducted in Italy, where Levofloxacin-based se-
quential regimens obtained >95% eradication rates, while
a Clarithromycin-based sequential regimen obtained
only an 80.8% success rate [10]. Other studies showed
the same superiority for Levofloxacin-based triple and
sequential regimens [11–14]. A recently published meta-
analysis compared Levofloxacin-based sequential therapy
and Clarithromycin-based triple and sequential treat-
ment, and revealed superiority for the regimens that
included fluoroquinolones (87.8% vs. 71.1%, respectively)
[15]. This is probably due to the very low resistance to
Levofloxacin reported in such studies (as low as 3.7% in
the Italian study by Romano et al [10]).
The patients included in our study were treated with
Metronidazole 500 mg in an 8–8 h or 12–12 h or with
Tinidazole 500 mg 12–12 h. Tinidazole was chosen
more often in both groups, but this preference was only
significant in the LST group. When comparing both
antibiotics, Metronidazole was inferior to Tinidazole in
the SST group. This difference is probably due to the
use of lower doses of Metronidazole (1000 mg) in almost
Table 2 Potential risk factors associated with eradication failure
Group A (n = 100)
Standard Sequential Therapy
Group B (n = 100)
Levofloxacin-based Sequential
Success (n = 90) Failure (n = 10) p/OR (95%CI) Success (n = 79) Failure (n = 21) p/OR (95%CI)
Age 52.1 ± 1.8 55,5 ± 3,8 0.528 55.7 ± 1.6 47.7 ± 3.9 0.068
>65 years 23 (25.6%) 2 (20%) 0.720 23 (29.1%) 7 (33.3%) 0.708
Female 50 (55.6%) 5 (50%) 0.738 49 (62%) 11 (52.4%) 0.423
Smoking habits 6 (6.7%) 2 (20%) 0.182 5 (6.3%) 3 (14.3%) 0.359
Alcohol consumption 16 (17.8%) 3 (30%) 0.350 8 (10.1%) 2 (9.5%) 0.952
Non-ulcer dyspepsia 14 (17.9%) 0 0.353 63 (83.3%) 20 (95.2%) 0.112
Metronidazole
(vs. Tinidazole)
38 (42.2%) 9 (90%) 0.006/10.15
(1.34–77.15)




7 (7.8%) 7 (70%) 0.001/ 8.25
(1.95–34.89)
4 (25%) 0 0.964
1st Generation PPI
(vs. 2nd Generation)
74 (82.2%) 7 (70%) 0.396 69 (87.3%) 20 (95.2%) 0.450
Half-dose PPI
(vs. full-dose)
4 (4.4%) 5 (50%) 0.001/ 10.11
(3.60–28.41)




20 (22.2%) 1 (10%) 0.684 2 (2.5%) 4 (19%) 0.017/3.68
(1.81–7.50)
CI95% 95% confidence interval, OR odds ratio, PPI proton-pump inhibitor
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a quarter of the patients. It is known that resistance to
Metronidazole in southern European countries is over
30% [4, 16], but can be overcome by using longer treat-
ments or higher doses of the drug. This hypothesis is
supported by the fact that high-dose Metronidazole
(1500 mg) obtained similar results to Tinidazole. This
difference in efficacy when using different Metronidazole
dosages was not observed in the LST group, probably
due to the low number of patients treated with Metro-
nidazole (19%), not allowing for statistically significant
differences to be noted.
When facing high resistance levels to Metronidazole, it
has been suggested that the optimum duration of quad-
ruple therapies should be 14 days, combined with high
doses of the drug (up to 1500–1600 mg in divided dos-
ages) [17]. Despite being recommended to avoid 10-day
sequential treatment if Metronidazole resistance is over
20%, in our population a 90% eradication rate was
obtained nevertheless.
Besides antibiotic resistance, there are other factors
that may contribute to treatment failure. Smoking is
often associated with unsuccessful eradication [18, 19],
but this was not the case in our study, probably due to
the low number of smokers included in our sample
population. Non-ulcer dyspepsia patients also tend to
respond worse to eradication treatment, when compared
to those with peptic ulcers [20], but this tendency was
not observed in our study groups. There was also no
difference in eradication rates for patients submitted to
treatment for hematologic conditions such as anemia
or thrombocytopenia. In fact, the most consistent factor
that influenced eradication success for both groups was
the proton-pump inhibitor (PPI) dose. The crucial role
of acid inhibition in optimizing the action of antibiotics
such as Amoxicillin led to the recommendation of
twice-daily full-dose PPI regimen [5, 21]. While the use
of full-dose PPI is widely recommended, the need to
use more recent PPI’s instead of first-generation drugs
is more controversial. A meta-analysis by McNicholl et
al [22], revealed superiority of esomeprazole and rabe-
prazole, but other studies failed to show the same bene-
fit [23]. Using new-generation PPI’s may be more
beneficial in populations where CYP2C19 extensive
metabolizer phenotype is prevalent [24]. In our popula-
tion the use of new-generation PPI’s was not associated
with a higher eradication rate. Another interesting find-
ing was the difference in the eradication rates obtained
by Gastroenterologists and non-Gastroenterologists in
the LST group. While there is no obvious explanation
for this difference, it has been suggested that providing
the patient with a written plan with prescription details
and warning about expected adverse effects may
improve adherence and therefore may contribute to
eradication success [25, 26].
Our study has some limitations. The strict non-adherence
definition used in our study led to the exclusion of a signifi-
cant number of patients. Furthermore, to obtain two groups
with similar dimension, a randomized sampling of patients
was performed. Despite these constraints, our study groups’
size is within range when compared to other published
studies [4, 12, 16, 25]. Its’ retrospective nature does not
allow comparison in intention-to-treat and per-protocol
analysis and H. pylori antibiotic resistance was not deter-
mined for each included patient.
Conclusions
We can conclude that standard sequential treatment was
quite effective and achieved an eradication rate that reached
the threshold of 90%, despite Metronidazole resistance over
20% and simultaneous resistance to Clarithromycin and
Metronidazole over 5% in our country. Full-dose PPI and a
higher dose of Metronidazole should be adopted to insure
positive outcomes. Levofloxacin-based sequential regimen
achieved an eradication rate under 80% and should not be
considered as first-line therapy.
To achieve such results with standard sequential ther-
apy, a full-dose of PPI and high doses of Metronidazole
or Tinidazole should be used. Despite adequate success
rate demonstrated by Clarithromycin-based sequential
therapy, a prospective study comparing different non-
bismuth quadruple therapies (sequential, hybrid and
concomitant) should be conducted in the near future to
find out which is the most effective in a country with
high Clarithromycin and Levofloxacin resistance such as
Portugal.
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